Overview
Short Course: October 15 | Virtual
Short Course: October 16 | Virtual
Conference: October 24-25 | In-Person
In an ever-evolving healthcare landscape, real-world evidence (RWE) has emerged as a pivotal tool for shaping regulatory and reimbursement decisions. Traditionally associated with post-market safety monitoring, RWE now plays a critical role throughout the entire product development lifecycle. It enables real-time data analysis to enhance our understanding of diseases, refine treatment approaches, and substantiate coverage decisions.
DIA’s Real-World Evidence Conference is designed to delve into the latest advancements and innovative applications of RWE. From data standards, new regulatory guidances, and advanced approaches for noninterventional studies to the role of RWD in clinical trial diversity, this conference will provide participants with cutting-edge insights into how RWE is transforming drug development and regulatory practices. By exploring new methodologies, technological advancements, and practical case studies, the event will equip attendees with the knowledge and tools necessary to leverage RWE effectively and drive forward healthcare decision-making. Don’t miss this opportunity to stay ahead in the field and harness RWE’s full potential to impact patient outcomes and policy.
Need Approval in Order to Attend?
Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Participant Testimonials
DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees. – Nicholaas Honig, JD, Senior Regulatory Counsel, Aetion
Great meeting. Very strong content. Was a really efficient way for me to catch up on RWD/E happenings over the past year! – Meredith Zozus, PhD, Professor; Division Chief and Director, Clinical Research Informatics, University of Texas Health Science Center
Check out the great content lined up for DIA'sn Real-World Evidence Conference.
Program Chair Welcome Video
Program Committee
-
David Martin, MD, MPH Vice President, Head, PCO Center of Excellence
Novartis, United States -
Jaclyn Bosco, PhD, MPH, FISPE Vice President, Global Head of Epidemiology & Database Studies
IQVIA, United States -
John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA, United States -
Diane Gubernot, DrPH, MPH Epidemiologist
US FDA, United States -
Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
Duke-Robert J. Margolis, MD, Center for Health Policy, United States -
Camille Jackson Director, Regulatory Policy; Legal and Regulatory
Flatiron Health , United States -
Charles Lee, MBA, MS Executive Regulatory Science Director
AstraZeneca, United States -
SARAH K Martin, PhD, MS Senior Director - Global Regulatory Policy (Oncology)
Eli Lilly & Co., United States -
Brittany Avin McKelvey, PhD Director, Regualtory Affairs
Friends of Cancer Research, United States -
Keri Monda, PhD, MS Executive Director, Center for Observational Research
Amgen, United States -
Representative Invited DIA, United States -
Representative Invited DIA, United States
Have an account?